Search results for " Colon"

showing 10 items of 718 documents

Functional Improvement after Photothrombotic Stroke in Rats Is Associated with Different Patterns of Dendritic Plasticity after G-CSF Treatment and G…

2016

We have previously shown that granulocyte-colony stimulating factor (G-CSF) treatment alone, or in combination with constraint movement therapy (CIMT) either sequentially or concomitantly, results in significantly improved sensorimotor recovery after photothrombotic stroke in rats in comparison to untreated control animals. CIMT alone did not result in any significant differences compared to the control group (Diederich et al., Stroke, 2012;43:185-192). Using a subset of rat brains from this former experiment the present study was designed to evaluate whether dendritic plasticity would parallel improved functional outcomes. Five treatment groups were analyzed (n = 6 each) (i) ischemic contr…

0301 basic medicineMalemedicine.medical_specialtyLightmedicine.medical_treatmentMovement10208 Institute of NeuropathologyIschemialcsh:Medicine610 Medicine & health1100 General Agricultural and Biological Sciences03 medical and health sciences0302 clinical medicine1300 General Biochemistry Genetics and Molecular BiologyInternal medicineNeuroplasticityGranulocyte Colony-Stimulating FactormedicineAnimalscardiovascular diseasesRats Wistarlcsh:ScienceSalineStrokePhysical Therapy Modalities1000 MultidisciplinaryMultidisciplinaryNeuronal Plasticitybusiness.industryPyramidal Cellslcsh:RDendritesRecovery of Functionmedicine.diseaseCombined Modality TherapyCortex (botany)SurgeryGranulocyte colony-stimulating factorConstraint-induced movement therapyStroke030104 developmental biologyEndocrinologyConcomitant570 Life sciences; biologylcsh:Qbusiness030217 neurology & neurosurgeryResearch ArticlePLoS ONE
researchProduct

Fate-Mapping of GM-CSF Expression Identifies a Discrete Subset of Inflammation-Driving T Helper Cells Regulated by Cytokines IL-23 and IL-1β.

2019

Summary Pathogenic lymphocytes initiate the development of chronic inflammatory diseases. The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) (encoded by Csf2) is a key communicator between pathogenic lymphocytes and tissue-invading inflammatory phagocytes. However, the molecular properties of GM-CSF-producing cells and the mode of Csf2 regulation in vivo remain unclear. To systematically study and manipulate GM-CSF+ cells and their progeny in vivo, we generated a fate-map and reporter of GM-CSF expression mouse strain (FROG). We mapped the phenotypic and functional profile of auto-aggressive T helper (Th) cells during neuroinflammation and identified the signature and pa…

0301 basic medicineMalemedicine.medical_treatmentImmunologyInterleukin-1betaInflammation610 Medicine & health10071 Functional Genomics Center ZurichBiology10263 Institute of Experimental Immunology03 medical and health sciencesInterferon-gammaMice0302 clinical medicineFate mappingImmunopathologymedicineInterleukin 23Immunology and AllergyAnimalsReceptorNeuroinflammationReceptors CXCR6InflammationMice KnockoutReceptors Interleukin-1 Type I2403 ImmunologyTumor Necrosis Factor-alphaGranulocyte-Macrophage Colony-Stimulating Factor2725 Infectious DiseasesReceptors InterleukinTh1 CellsPhenotype3. Good healthCell biology10040 Clinic for NeurologyMice Inbred C57BL030104 developmental biologyInfectious DiseasesCytokine030220 oncology & carcinogenesis2723 Immunology and AllergyInterleukin-23 Subunit p19570 Life sciences; biologyTh17 CellsFemalemedicine.symptomImmunity
researchProduct

Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse a…

2017

B-cell activating factor of the tumour necrosis factor family (BAFF) is a cytokine, mainly produced by hematopoietic cells (e.g. monocytes/macrophages, dendritic cells), indispensable for B-cell maturation. The BLISS studies have demonstrated that blocking BAFF by the human monoclonal antibody belimumab is a valuable therapeutic approach in patients with clinically and serologically active systemic lupus erythematosus (SLE). However, the defined sources of BAFF, which contributes to SLE, are still unclear. Recent findings show that BAFF expression is not restricted to myeloid cells. Since lupus nephritis is the main cause of morbidity and mortality for SLE patients, the aim of this study wa…

0301 basic medicineMalemedicine.medical_treatmentLupus nephritisAntibodies Monoclonal HumanizedKidneySeverity of Illness IndexPathogenesis03 medical and health sciencesMice0302 clinical medicinestomatognathic systemRheumatologyimmune system diseasesB-Cell Activating FactormedicineAnimalsHumansLupus Erythematosus Systemicskin and connective tissue diseasesB-cell activating factorAutocrine signallingRetrospective StudiesB-Lymphocytesbusiness.industryTumor Necrosis Factor-alphaEpithelial Cellsmedicine.diseaseBelimumabLupus Nephritisstomatognathic diseasesHaematopoiesis030104 developmental biologyCytokineReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologyCytokinesTumor necrosis factor alphaFemaleKidney DiseasesbusinessImmunosuppressive Agents030215 immunologymedicine.drugLupus
researchProduct

Invasive candida infections in neonates after major surgery: Current evidence and new directions

2021

Infections represent a serious health problem in neonates. Invasive Candida infections (ICIs) are still a leading cause of mortality and morbidity in neonatal intensive care units (NICUs). Infants hospitalized in NICUs are at high risk of ICIs, because of several risk factors: broad spectrum antibiotic treatments, central catheters and other invasive devices, fungal colonization, and impaired immune responses. In this review we summarize 19 published studies which provide the prevalence of previous surgery in neonates with invasive Candida infections. We also provide an overview of risk factors for ICIs after major surgery, fungal colonization, and innate defense mechanisms against fungi, a…

0301 basic medicineMicrobiology (medical)Antifungalmedicine.medical_specialtymedicine.drug_classInvasive Candida infections030106 microbiologylcsh:MedicineInvasive Candida infectionCandida infections03 medical and health sciencesBroad spectrumNeonatal surgeryinvasive <i>Candida</i> infections0302 clinical medicineInvasive fungal infectionInvasive fungal infectionsIntensive careEpidemiologyFungal colonizationImmunology and AllergyMedicineAntifungal prophylaxi030212 general & internal medicineMolecular BiologyNewbornsGeneral Immunology and Microbiologybusiness.industrylcsh:RImpaired immune responsesNewbornSurgeryNeonatal surgeryInfectious DiseasesSettore MED/20SurgeryAntifungal prophylaxisAntifungal prophylaxis; Invasive Candida infections; Invasive fungal infections; Neonatal surgery; Newborns; Surgerybusiness
researchProduct

A Snapshot on MRSA Epidemiology in a Neonatal Intensive Care Unit Network, Palermo, Italy

2016

Objectives. We performed a one-year prospective surveillance study on MRSA colonization within the five NICUs of the metropolitan area of Palermo, Italy. The purpose of the study was to assess epidemiology of MRSA in NICU from a network perspective. Methods. Transfer of patients between NICUs during 2014 was traced based on the annual hospital discharge records. In the period February 2014 – January 2015, in the NICU B, at the University teaching hospital, nasal swabs from all infants were collected weekly, whereas in the other four NICUs (A, C, D, E) at four week-intervals of time. MRSA isolates were submitted to antibiotic susceptibility testing, SCCmec typing, PCR to detect lukS-PV and l…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyNeonatal intensive care unithealth care facilities manpower and services030106 microbiologylcsh:QR1-502MRSAMicrobiologylcsh:Microbiology03 medical and health sciencesInternal medicineEpidemiologyMedicineInfection controlnetwork approachOriginal ResearchNICuActive surveillance; Molecular typing; MRSA; Network approach; NICu; Microbiology; Microbiology (medical)business.industryMRSA colonizationactive surveillancemolecular typingSequence typesVariable number tandem repeat030104 developmental biologyMultilocus sequence typingUniversity teachingbusinessFrontiers in Microbiology
researchProduct

Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity

2016

SummaryThe extracellular matrix (ECM) contributes to the biological and clinical heterogeneity of breast cancer, and different prognostic groups can be identified according to specific ECM signatures. In high-grade, but not low-grade, tumors, an ECM signature characterized by high SPARC expression (ECM3) identifies tumors with increased epithelial-to-mesenchymal transition (EMT), reduced treatment response, and poor prognosis. To better understand how this ECM3 signature is contributing to tumorigenesis, we expressed SPARC in isogenic cell lines and found that SPARC overexpression in tumor cells reduces their growth rate and induces EMT. SPARC expression also results in the formation of a h…

0301 basic medicineMyeloidMDSCGene Expressionmedicine.disease_causeT-Lymphocytes RegulatoryPolyethylene GlycolsExtracellular matrixMiceBreast cancerMyeloid CellsOsteonectinMast Cellslcsh:QH301-705.5Mice KnockoutAntigen PresentationMice Inbred BALB CEMTepithelial to mesenchymal transitionBreast cancer; COX-2; CXCL12; ECM; EMT; G-CSF; GM-CSF; MDSC; SPARC; aminobisphosphonates; cyclooxygenase-2; epithelial to mesenchymal transition; extracellular matrix; granulocyte colony-stimulating factor; granulocyte-macrophage colony-stimulating factor; myeloid-derived suppressor cellsCXCL12Granulocyte macrophage colony-stimulating factormedicine.anatomical_structurecyclooxygenase-2granulocyte-macrophage colony-stimulating factorFemalegranulocyte colony-stimulating factormedicine.drugEpithelial-Mesenchymal Transitionextracellular matrixAntineoplastic AgentsBreast NeoplasmsBiologySettore MED/08 - Anatomia PatologicaG-CSFGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesCell Line TumormedicineAnimalsHumansEpithelial–mesenchymal transitionECMMesenchymal stem cellSPARCGM-CSFCOX-2myeloid-derived suppressor cellsXenograft Model Antitumor AssaysIsogenic human disease modelsaminobisphosphonates030104 developmental biologylcsh:Biology (General)CelecoxibDoxorubicinImmunologyCancer researchMyeloid-derived Suppressor CellaminobisphosphonateNeoplasm GradingCarcinogenesisCell Reports
researchProduct

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

2016

IF 5.008; International audience; Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor. These patients were treated with cetuximab or panitumumab alone or with chemotherapy as second or third-line. Univariate and multivariate Cox model analysis were performed to estimate the effect of a previous bevacizumab regimen on progression free survival a…

0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologyMaleVascular Endothelial Growth Factor AColorectal cancerCetuximabAngiogenesis Inhibitorsmedicine.disease_causeTrialGTP PhosphohydrolasesRas mutations[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsDrug InteractionsAged 80 and overCetuximabPanitumumabAntibodies MonoclonalMiddle Aged3. Good healthErbB ReceptorsOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasms1st-Line treatmentmedicine.drugResearch PaperAdultSTAT3 Transcription Factormedicine.medical_specialtyBevacizumabAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabIrinotecanDisease-Free SurvivalTumor angiogenesisProto-Oncogene Proteins p21(ras)03 medical and health sciencesVEGFRInternal medicineCell Line TumormedicinePanitumumabHumansEndothelial growth-FactorChemotherapyProgression-free survivalAgedbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMembrane Proteinsmetastatic colon cancerStat-3medicine.diseaseVascular Endothelial Growth Factor Receptor-2IrinotecanRandomized phase-III030104 developmental biologyanti-EGFR therapyFactor receptorCaco-2 Cellsbusiness
researchProduct

JNK pathway and heat shock response mediate the survival of C26 colon carcinoma bearing mice fed with the mushroom Pleurotus eryngii var. eryngii wit…

2021

In the last few years, there has been emerging interest in developing treatments against human diseases using natural bioactive content. Here, the powder of the edible mushroom Pleurotus eryngii var. eryngii was mixed with the normal diet of mice bearing C26 colon carcinoma. Interestingly, it was evidenced by a significant increase in the survival rate of C26 tumor-bearing mice accompanied by a significant increase in Hsp90 and Hsp27 protein levels in the tumors. These data were paralleled by a decrease in Hsp60 levels. The mushroom introduced in the diet induced the inhibition of the transcription of the pro-inflammatory cytokines IL-6 and IL-1 exerting an anti-inflammatory action. The eff…

0301 basic medicineNormal dietMAP Kinase Signaling SystemPharmacologyPleurotus03 medical and health sciencesMice0302 clinical medicineHsp27SurvivinAnimalsPleurotus eryngiiHeat shockMushroomMice Inbred BALB CbiologyKinaseGeneral MedicineJNK Pleurotus eryngii cachexia C26 colon carcinomabiology.organism_classificationEdible mushroomDisease Models Animal030104 developmental biology030220 oncology & carcinogenesisColonic NeoplasmsDietary Supplementsbiology.proteinFemaleHeat-Shock ResponseFood SciencePhytotherapyFoodfunction
researchProduct

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

2016

// Giulia Bon 1, * , Rossella Loria 1, * , Carla Azzurra Amoreo 2 , Alessandra Verdina 1 , Isabella Sperduti 2 , Arianna Mastrofrancesco 3 , Silvia Soddu 1 , Maria Grazia Diodoro 2 , Marcella Mottolese 2 , Matilde Todaro 4 , Giorgio Stassi 4 , Michele Milella 5 , Ruggero De Maria 6 , Rita Falcioni 1 1 Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy 2 Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy 3 Physiopathology Laboratory of Skin, IRCCS San Gallicano Dermatological Institute, Rome, Italy 4 Surgical and Oncological Scien…

0301 basic medicineOncologyMAPK/ERK pathwaymedicine.medical_specialtyPatritumabColorectal cancerHER3; MAPK; PI3K; colon cancers; drug resistanceDrug resistancePI3K03 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEcolon cancersHER3Internal medicinemedicineColon cancers; Drug resistance; HER3; MAPK; PI3K; Oncologyskin and connective tissue diseasesPI3K/AKT/mTOR pathwayTrametinibSettore MED/06 - ONCOLOGIA MEDICAdrug resistancebusiness.industryCancermedicine.diseaseMAPKbody regionsClinical trial030104 developmental biologyOncologycolon cancerbusinessResearch Paper
researchProduct

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy

2017

Abstract Purpose: There are conflicting results concerning the prognostic value of the CpG island methylator phenotype (CIMP) in patients with nonmetastatic colon cancer. We studied this phenotype in stage III colon cancer characterized for mismatch repair (MMR), RAS, and BRAF status, and treated with adjuvant FOLFOX-based regimen. Experimental Design: Tumor samples of 1,907 patients enrolled in the PETACC-8 adjuvant phase III trial were analyzed. The method used was methylation-specific PCR, where CIMP+ status was defined by methylation of at least 3 of 5 following genes: IGF2, CACNA1G, NEUROG1, SOCS1, and RUNX3. Association between CIMP status and overall survival (OS), disease-free survi…

0301 basic medicineOncologyMaleCancer ResearchOrganoplatinum CompoundsAdjuvant chemotherapyColorectal cancermedicine.medical_treatmentLeucovorincolon cancer stage iiiKaplan-Meier EstimateDNA Mismatch Repair[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMethylator phenotypecolorectalCetuximabHematologyMiddle AgedColon cancer stage iiiPrognosisPhenotypeStage III Colon Cancer3. Good healthadjuvant chemotherapyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsoncologyFemaleFluorouracilmedicine.drugmedicine.medical_specialtyphenotype[SDV.CAN]Life Sciences [q-bio]/CancerGastrointestinal tumoursDisease-Free Survivalpatient prognosis03 medical and health sciencesInternal medicinemedicineHumansneoplasmsAgedNeoplasm StagingChemotherapyCpG Island Methylator Phenotypebusiness.industryProportional hazards modeloxaliplatinCancerDNA Methylationmedicine.diseasedigestive system diseasesOxaliplatin030104 developmental biologyMutationCpG IslandsNeoplasm Recurrence LocalbusinessValue (mathematics)030217 neurology & neurosurgery
researchProduct